Important Notice for Neumora Therapeutics, Inc. Shareholders
NEW YORK, March 31, 2025:
The Gross Law Firm, a leading securities litigation law firm, today notified shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA) that they may be entitled to compensation following allegations of securities fraud against the company. The class period for this potential securities class action covers investors who purchased NMRA shares between January 1, 2023, and December 31, 2024.
Background
Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of neurodegenerative diseases. The company’s lead product candidate, NT-501, is a novel small molecule drug designed to address a specific protein misfolding process believed to be involved in several neurodegenerative diseases. Neumora Therapeutics went public in 2022 through a reverse merger with a special purpose acquisition company (SPAC).
Alleged Securities Fraud
The Gross Law Firm’s investigation focuses on allegations that Neumora Therapeutics and certain of its executives may have made false and/or misleading statements and/or failed to disclose material adverse facts about the company’s business, operations, and financial condition. Specifically, the firm is investigating whether the defendants made false and/or misleading statements and/or failed to disclose: (1) that there were significant issues with the manufacturing and production of NT-501; and (2) that, as a result of these issues, the company’s clinical trials for NT-501 were likely to be delayed.
Possible Lead Plaintiff Appointment
If you purchased shares of Neumora Therapeutics, Inc. during the class period and suffered a loss, you may be entitled to compensation. The Gross Law Firm is seeking to appoint a lead plaintiff to represent the class. If you wish to serve as the lead plaintiff, please contact the firm as soon as possible. You may also contact the firm to discuss your rights and potential remedies as a shareholder.
Impact on Individual Shareholders
If the allegations of securities fraud are proven, shareholders who purchased NMRA shares during the class period may be able to recover their losses. The value of their shares may have been artificially inflated due to the false and/or misleading statements made by Neumora Therapeutics and its executives. Shareholders who suffered losses as a result of these alleged actions may be entitled to compensation.
Impact on the World
The potential securities fraud allegations against Neumora Therapeutics could have far-reaching implications. If the allegations are proven, it could damage the reputation of the biopharmaceutical industry as a whole, potentially discouraging investors from putting their money into biotech companies. It could also impact the development of NT-501 and other potential neurodegenerative disease treatments, as investors may become more cautious about investing in companies focused on these types of therapies.
Conclusion
The Gross Law Firm’s investigation into Neumora Therapeutics, Inc. is ongoing. If you purchased shares of NMRA during the class period and believe you may be entitled to compensation, please contact the firm as soon as possible. The potential securities fraud allegations against the company could have significant implications for individual shareholders and the biopharmaceutical industry as a whole.
Stay informed about this developing story and other important securities law news by following The Gross Law Firm on social media and signing up for email updates at [email protected].
- Neumora Therapeutics, Inc. (NASDAQ: NMRA)
- Securities fraud allegations
- Possible class action lawsuit
- Shareholders who purchased shares between January 1, 2023, and December 31, 2024, may be entitled to compensation
- Contact The Gross Law Firm for more information
